{"id":"NCT01235234","sponsor":"Can-Fite BioPharma","briefTitle":"Trial of CF101 to Treat Patients With Dry Eye Disease","officialTitle":"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-11","completion":"2013-12","firstPosted":"2010-11-05","resultsPosted":"2015-03-11","lastUpdate":"2022-06-30"},"enrollment":236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Keratoconjunctivitis Sicca"],"interventions":[{"type":"DRUG","name":"CF101","otherNames":["IB-MECA"]}],"arms":[{"label":"CF101 0.1 mg","type":"EXPERIMENTAL"},{"label":"CF101 1 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.","primaryOutcome":{"measure":"Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24","timeFrame":"24 weeks","effectByArm":[{"arm":"CF101 0.1 mg","deltaMin":15,"sd":null},{"arm":"CF101 1 mg","deltaMin":13,"sd":null},{"arm":"Placebo","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":1,"countries":["Israel"]},"refs":{"pmids":["20304499"],"seeAlso":["http://www.canfite.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":77},"commonTop":["Urinary tract infection"]}}